Cancer Immunoprevention Network (CIP-Net) Resource Coordinating Center (U24 Clinical Trials Not Allowed)
ID: 356572Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356572

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-036.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity to establish the Cancer Immunoprevention Network (CIP-Net) Resource Coordinating Center (CIP-Net DRCC) through a cooperative agreement. This initiative aims to enhance collaborative research in cancer immunoprevention by providing data coordination, scientific outreach, and support for early career scientists, while also mandating a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity. Eligible organizations can apply for funding of up to $499,999 annually for a maximum of five years, with a total of $850,000 allocated for one award in FY 2025. Interested applicants must submit their proposals by December 2, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-036-Full-Announcement.html
    RFA-CA-24-036.html
    The National Cancer Institute (NCI) has issued a Notice of Funding Opportunity (NOFO) to establish the Cancer Immunoprevention Network (CIP-Net) and its Data and Resource Coordinating Center (DRCC). This initiative aims to enhance collaborative cancer immunoprevention research by providing resource coordination, scientific outreach, and support for early career scientists. The NOFO outlines two phases of research projects for immunoprevention and mandates a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity. The DRCC will be responsible for coordinating research efforts, enhancing communication, and developing resources for data sharing among investigators. Eligible organizations can apply for up to five years of funding, not exceeding $499,999 annually, with a total of $850,000 dedicated for one award in FY 2025. The application process requires compliance with NIH policies, including a detailed review of the applicants' organizational capabilities and strategies for achieving the program's goals. The emphasis on community engagement and integrating diverse perspectives reflects the NIH's commitment to advancing innovative research strategies and improving health outcomes.
    Similar Opportunities
    Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Cancer Prevention Clinical Trials Network (CP-CTNet) to establish sites for early-phase cancer prevention clinical trials. The initiative aims to develop and conduct trials that assess the safety and efficacy of various preventive agents and interventions targeting specific biological processes associated with cancer development, with a focus on recruiting high-risk participants and conducting multi-institutional studies. This funding underscores the importance of advanced research in cancer prevention, with a total funding amount of $8.75 million annually to support five awards over six years, each with a budget not exceeding $1.375 million. Interested applicants must submit a letter of intent by August 23, 2024, and a complete application by September 30, 2024; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Cancer Prevention Clinical Trials Network (CP-CTNet) to establish a Data Management, Auditing, and Statistical Center (DMASC) through a cooperative agreement. This initiative aims to support the design and execution of early-phase clinical trials focused on cancer prevention strategies, assessing the safety, tolerability, and efficacy of various interventions while enhancing operational efficiencies and data integration across the network. The DMASC will play a crucial role in providing centralized data management, auditing clinical trial processes, and offering statistical support, ultimately addressing significant public health challenges related to cancer prevention. The project is set for a six-year period with an annual funding commitment of $3,250,000, and interested applicants must submit their proposals by October 31, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery and Development of Natural Products for Cancer Interception and Prevention" under the cooperative agreement mechanism. This initiative aims to support innovative projects that focus on the discovery and development of novel natural products that are safe, nontoxic, and effective in intercepting or preventing cancer, with a structured approach divided into two phases: the UG3 phase for initial target selection and assay validation, followed by the UH3 phase for large-scale evaluations and pharmacokinetic assessments. The total funding available for this program is $4.5 million over the fiscal years 2024 to 2026, with a deadline for applications set for June 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)" aimed at fostering collaborations between institutions serving underserved populations and NCI-designated Cancer Centers. The initiative seeks to enhance cancer research capacity, promote workforce diversity, and implement community outreach initiatives to address cancer health disparities. This program is vital for developing comprehensive research projects that include administrative cores, research education, and outreach efforts, ultimately contributing to a stronger national cancer program. Eligible applicants can request funding of up to $2.2 million over five years, with the application submission period starting on December 15, 2023. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at enhancing clinical trials focused on cancer prevention and control. This program seeks to address critical gaps in knowledge regarding study populations, interventions, and operational challenges, facilitating the collection of essential data to finalize protocols for future clinical trials. The initiative is particularly important for improving cancer-related health behaviors, screening, and the long-term outcomes of cancer survivors. Eligible applicants include a diverse range of organizations, with funding available up to $600,000 over three years, and applications are due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source: NCI National Clinical Trials Network - Network Radiotherapy and Imaging Core Services Centers (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a funding opportunity announcement for a cooperative agreement aimed at establishing a Network Radiotherapy and Imaging Core Services Center under the NCI National Clinical Trials Network (NCTN). This center will provide essential scientific and technical expertise for quality control, assurance, and image data management in NCTN trials that involve radiotherapy and imaging modalities, as well as support for other NCI-supported clinical trial programs. The funding opportunity is significant for enhancing cancer treatment research and is expected to have a total program funding of $8.8 million, with a ceiling of $8.14 million for the award. Interested private institutions of higher education should prepare their applications, as the anticipated application due date is in late February 2025, with an estimated award date set for March 1, 2026.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Discovery and Development of Natural Products for Cancer Interception and Prevention, specifically through a cooperative agreement mechanism. This initiative aims to support the discovery and development of novel, safe, and effective natural products that target cancer prevention, structured in two phases: the UG3 phase for initial screenings and assay development lasting up to three years, followed by the UH3 phase for full-scale evaluations lasting up to two years. The program emphasizes the importance of high-throughput screening strategies and collaboration with existing NCI natural product libraries, with a total funding allocation of $4.5 million for approximately 12 awards. Interested applicants must submit their proposals by June 13, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for the establishment of Network Lead Academic Participating Sites (LAPS) within the National Clinical Trials Network (NCTN) to enhance cancer clinical trials for adult patients. This initiative aims to foster scientific leadership and collaboration among U.S. Network Groups, with a focus on robust trial accrual and outreach to underrepresented populations. The NCI plans to allocate up to $35.1 million to support 32 to 40 awards, with each award having a maximum budget of $1.7 million per year over a six-year project period. Interested applicants can find more information and application guidelines at the provided link, with proposals due by February 24, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.